Avid Bioservices Inc (CDMO)

[biopharm]

BetaBodies jumping Bavituximab!
...
...

Very interesting notes from above post and I was tossed a curve ball when Biogen now filing for FDA approval in Alzheimer's when we all know the drug must pass the blood brain barrier to have success so I am not including hires to Biogen that KNOW PS Targeting ....but who finds it interesting that another IDMC got the result wrong? Just like the IDMC on Sunrise got it wrong because they were not attuned to how IO works and not attuned to BIOMARKERS based upon PS Targeting

Now in November we hear about Betabodies ! And they surely pass the BBB blood brain barrier

So March 2019 some BPs think Biogen Alzheimer's venture ends...till now and I see many puzzle pieces intact as Ampersand went to buy Merck Keytruda sidekick CGI via Interpace Diagnostics

____________

March 21, 2019 at 7:00 AM EDT
Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials

CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimerâ??s disease and mild Alzheimerâ??s disease dementia. The decision to stop the trials is based on results of a futility analysis conducted by an independent data monitoring committee, which indicated the trials were unlikely to meet their primary endpoint upon completion. The recommendation to stop the studies was not based on safety concerns.
..
..

http://investors.biogen.com/news-releases/news-release-details/biogen-and-eisai-discontinue-phase-3-engage-and-emerge-trials

_________


And as for betabodies...

Nov 11, 2019 | 17:00 Pharmazeutisches Kolloquium: Beta-Bodies, a New Class of Recognition Molecules (Lecture)


Pharmazeutisches Kolloquium:

Beta-Bodies, a New Class of Recognition Molecules
Lecture

Referee: Prof. Dr. Morten Meldal Department of Chemistry and Nano Science Center University of Copenhagen

Location: Pharmazeutsches Institut

Address: Gerhard-Domagk-StraÃ?e 3

Room: HS2

Event host: Pharma-Zentrum Bonn / BIGS DrugS

https://www.bfb.uni-bonn.de/veranstaltungen/copy8_of_pharmazeutisches-kolloquium-taspase-1-a-201emisunderstood201c-protease-of-relevance-for-cancer-therapy

__________

So who has Betabodies and Who is failing to maximize shareholder value ? You have it... Ampersand

Who knows...maybe Ampersand Capital is on some deep state rogue mission to announce that recent CDMO contracts coming are all due to PS Targeting and betabodies ....or were the CDMO contracts more like a bribe to hush hush the data and steer it into another Merckly corner ? because any one can see 3 Merck trials going on with Bavituximab right now but that means Ampersand working with Oncologie Inc via a back channel ...more to come

__________

AVID BIOSERVICES AND ONCOLOGIE ENTER INTO ASSET ASSIGNMENT AND PURCHASE AGREEMENT FOR AVIDâ??S PS-TARGETING PROGRAM INCLUDING BAVITUXIMAB

On February 12, 2018 Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) ("Avid") and Oncologie, Inc. reported that the companies have entered into an Asset Assignment and Purchase Agreement for Avidâ??s phosphatidylserine (PS)-targeting program including bavituximab (Press release, Peregrine Pharmaceuticals, FEB 12, 2018, View Source [SID1234523979]). Bavituximab is an investigational immune-modulatory monoclonal antibody that targets PS, a phospholipid that inhibits the ability of immune cells to recognize and fight tumors. In addition to bavituximab, the deal includes Avidâ??s other PS-targeting antibodies, including betabodies, as well as certain other assets and licenses useful and/or necessary for the potential commercialization of bavituximab.


https://www.bfb.uni-bonn.de/veranstaltungen